FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma
Authors:
- Marc RemkeMRMarc Remke
- Thomas HielscherTHThomas Hielscher
- Andrey KorshunovAndrey Korshunov
- Paul A. NorthcottPNPaul A. Northcott
- Sebastian BenderSBSebastian Bender
- Marcel KoolMKMarcel Kool
- Frank WestermannFWFrank Westermann
- Axel BennerABAxel Benner
- Huriye CinHCHuriye Cin
- Marina RyzhovaMRMarina Ryzhova
- Dominik SturmDSDominik Sturm
- Hendrik WittHWHendrik Witt
- 10 October 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (29) , 3852-3861
Abstract
Purpose: Integrated genomics approaches have revealed at least four distinct biologic variants of medulloblastoma: WNT (wingless), SHH (sonic hedgehog), group C, and group D. Because of the remarkable clinical heterogeneity of group D tumors and the dismal prognosis of group C patients, it is vital to identify molecular biomarkers that will allow early and effective treatment stratification in these non-WNT/non-SHH tumors. Patients and Methods: We combined transcriptome and DNA copy-number analyses for 64 primary medulloblastomas. Bioinformatic tools were used to discover marker genes of molecular variants. Differentially expressed transcripts were evaluated for prognostic value in the screening cohort. The prognostic power of follistatin-like 5 (FSTL5) immunopositivity was tested for 235 nonoverlapping medulloblastoma samples on two independent tissue microarrays. Results: Comprehensive analyses of transcriptomic and genetic alterations delineate four distinct variants of medulloblastoma. Stable subgroup separation was achieved by using the 300 transcripts that varied the most. Distinct expression patterns of FSTL5 in each molecular subgroup were confirmed by quantitative real-time polymerase chain reaction. Immunopositivity of FSTL5 identified a large cohort of patients (84 of 235 patients; 36%) at high risk for relapse and death. Importantly, more than 50% of non-WNT/non-SHH tumors displayed FSTL5 negativity, delineating a large patient cohort with a good prognosis who would otherwise be considered intermediate or high-risk on the basis of current molecular subgrouping. Conclusion: FSTL5 expression denoted a dismal prognosis both within and across medulloblastoma subgroups. The addition of FSTL5 immunohistochemistry to existing molecular stratification schemes constitutes a reliable and cost-effective tool for prognostication in future clinical trials of medulloblastoma.Keywords
This publication has 34 references indexed in Scilit:
- Medulloblastoma Comprises Four Distinct Molecular VariantsJournal of Clinical Oncology, 2011
- Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk StratificationJournal of Clinical Oncology, 2010
- Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the MYC and MYCN LociJournal of Clinical Oncology, 2009
- Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratificationNature Clinical Practice Oncology, 2007
- Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable PrognosisCell Cycle, 2006
- β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour CommitteeJournal of Clinical Oncology, 2005
- Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma PatientsClinical Cancer Research, 2005
- Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for MedulloblastomaJournal of Clinical Oncology, 2004
- Clinical and molecular stratification of disease risk in medulloblastomaBritish Journal of Cancer, 2001
- Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome.Journal of Clinical Oncology, 1998